ArticleScientific reports2025
Assessment of quality in volatile oil from three basic sources of Xinyi from Hubei by anatomy, GC-MS, and chemometric methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Development and Characterization ofPharmaceutics · 2025Article
- Phytochemical Characterization, Antioxidant Activity, and Anti-Melanoma Mechanism of Flower Buds ofPlants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
"Xinyi" (Magnolia biondii Pampan., Magnolia denudata Desr., and Magnolia sprengeri Pampan.) is a traditional Chinese medicine listed in the Pharmacopoeia of the People's Republic of China. "Xinyi" has anti-inflammatory, anti-allergic, antioxidant, and antibacterial effects, and has significant curative effects in the treatment of acute and chronic rhinitis, allergic rhinitis, and other rhinitis symptoms. However, comparative quality assessments of these three species are scarce. This study investigated the variations in the volatile oil content and composition in the flower buds of M. biondii, M. denudata, and M. sprengeri using the gas chromatography-mass spectrometry (GC-MS) and the microscopic analysis at different growth stages. This study indicated the following findings. (1) The volatile oil levels varied among the species, with M. biondii, M. denudata, and M. sprengeri peaking, respectively. In addition, the cell density was positively correlated with the oil deposition. (2) The content of 1,8-Cineole varied significantly, where M. biondii exhibited the high levels at 14.50% at stage 4 and 16.40% at stage 5; M. denudata peaked at 17.87% at stage 5; and M. sprengeri was 1.07% at stage 3. Moreover, M. biondii and M. denudata from Hubei exceeded the Pharmacopoeia's 1% standard, whereas M. sprengeri did not. These findings underscore the need to improve the herb production standards and provide valuable data for assessing the therapeutic potential of these "Xinyi" species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.